Wedbush analyst Yun Zhong has maintained their bullish stance on BMRN stock, giving a Buy rating on September 5.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong has given his Buy rating due to a combination of factors that highlight BioMarin Pharmaceutical’s potential for growth and success. The company has presented promising data from its Phase 3 study of Palynziq in adolescent patients, demonstrating strong efficacy in reducing blood Phe levels compared to diet alone. This data supports the potential for regulatory approval for label expansion in 2026, which could significantly increase the eligible patient population and drive revenue growth.
Additionally, BioMarin’s enzyme therapies have shown robust revenue growth, with a 15% year-over-year increase in the second quarter of 2025, and Palynziq’s revenue alone increased by 20%. The company’s strategic initiatives, including expanding into emerging markets and increasing patient compliance, further bolster its growth prospects. Upcoming catalysts, such as the potential launch of BMN 401 in 2027 and data from other pipeline products, also contribute to a positive outlook for BioMarin, supporting Yun Zhong’s Buy rating.
In another report released on September 5, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $64.00 price target.